photo Utusan
Just imagine how your life if lost senses of sight, using a wheelchair due to a stroke or gangrene leg (leg cut) in addition to high-risk heart attack while not yet reached 40 years of age.
That's what awaits diabetes patients due to failing to control the disease, whether through lifestyle changes, not wanting to take medication or take traditional medicine will.
Situation is exacerbated if among them were diagnosed with diabetes from an early age.
Diabetes mellitus is a metabolic problem that causes the syndrome level high blood sugar (hyperglycemia) whether due to production problems (diabetes first type) or function (sensitivity) of insulin (diabetes or gestational diabetes of the second kind).
Most adults have diabetes mellitus type 2 (T2DM).
However, many people with T2DM can not control the disease with anti-diabetic drugs, respectively, they run the risk of complications.
Professor of Diabetes Medicine University of Leicester, Professor Melanie Davies told at least 67 percent of people with T2DM risk of deterioration of renal function is high and about 30 percent have experienced deterioration in the United States.
Meanwhile, eight to 10 diabetic patients with renal impairment have a higher risk of serious complications such as hypoglycemia and cardiovascular disease conditions.
"Therefore, patients in dire need of oral anti-diabetic drugs (OAD) that can be trusted with the safety profile and better tolerance of an easy to use regardless of the patient's renal function.
"Most of the OAD is not recommended or require dose adjustment and close monitoring for creating significant barriers to people with T2DM with the deterioration," he said at the launch of the drug (T2DM) newest Trajenta by Boehringer Ingelheim and Eli Lilly.
Trajenta is approved as a treatment of diabetes medication dosage strength (five milligrams, once a day) for adult patients. The Drug Control Authority (DCA) under the Ministry of Health has approved Trajenta as recommended in adult patients with T2DM to improve glycemic control together with diet and exercise, as monotherapy single treatment or in addition to metformin, sulfonylureas or metformin and sulfonylureas.
Add Professor Melanie, Trajenta can be taken with a dose for all patients regardless of kidney or liver failure.
"It offers the benefits afforded by DPP-4 inhibitor class with the efficacy and good tolerance and neutral in terms of weight and create a low risk of hypoglycemia and also provides the added advantage of no dose adjustment regardless of the patient's kidney and liver function," he said.
These positive developments are sure to delight people with T2DM, especially in Asia because the spread of diabetes has increased from two to five times in the last two decades compared to 1.5 times in the West.
Furthermore, due to the side effects associated with inappropriate OAD, patients may find it difficult to comply with the recommended treatment. Compliance rates of patients with T2DM is between 65 percent to 85 percent for the OAD and 60 percent to 80 percent for insulin.
"Trajenta provide a variety of benefits that are effective and appropriate for most people with T2DM," said Managing Director of Boehringer Ingelheim Malaysia Sdn. Limited., Cheong YK.
He added that many people with diabetes are often concerned about weight gain or hypoglycemia which reduces compliance with medication.
"Trajenta no effect on weight when used as monotherapy and can be taken at any time, with or without food, providing better control of T2DM without compromising patient care," he added.
reference - Utusan
No comments:
Post a Comment